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Acute myeloid leukaemia (AML) is a heterogeneous neoplastic disorder in which a 
subset of cells function as leukaemia-initiating cells (LICs). In this study, we 
prospectively evaluated the leukaemia-initiating capacity of AML cells fractionated 
according to the expression of a nucleolar GTP binding protein, nucleostemin (NS). To 
monitor NS expression in living AML cells, we generated a mouse AML model in 
which green fluorescent protein (GFP) is expressed under the control of a region of the 
NS promoter (NS-GFP). In AML cells, NS-GFP levels were correlated with endogenous 
NS mRNA. AML cells with the highest expression of NS-GFP were very immature 
blast-like cells, efficiently formed leukaemia colonies in vitro, and exhibited the highest 
leukaemia-initiating capacity in vivo. Gene expression profiling analysis revealed that 
cell cycle regulators and nucleotide metabolism-related genes were highly enriched in a 
gene set associated with leukaemia-initiating capacity that we termed the ‘leukaemia 
stem cell gene signature’. This gene signature stratified human AML patients into 
distinct clusters that reflected prognosis, demonstrating that the mouse leukaemia stem 
cell gene signature is significantly associated with the malignant properties of human 
AML. Further analyses of gene regulation in leukaemia stem cells could provide novel 
insights into diagnostic and therapeutic approaches to AML. 
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Acute myeloid leukaemia (AML) is a heterogeneous neoplastic disorder characterized 
by substantial cellular heterogeneity. Only a rare subset of cells is assumed to have the 
ability to self-renew and to initiate and sustain the disease [1]. Understanding the 
functional regulatory machinery of these leukaemia initiating cells (LICs) is critically 
important for designing an efficient therapeutic approach, but these cells have not yet 
been characterized in detail. 
Nucleostemin (NS, also known as GNL3) encodes a GTP-binding protein that 
is mainly located in rRNA-free sites of the nucleolus [2]. NS contributes to ribosomal 
biogenesis by interacting with nucleolar proteins involved in pre-rRNA processing [3]. 
Moreover, NS is essential for the maintenance of nucleolar architecture and the integrity 
of nucleolar RNA-protein complexes [4]. NS also interacts with telomeric 
repeat-binding factor 1 (TRF1) to facilitate its degradation, which enhances the 
maintenance of telomere length [5]. NS and GNL3L form a complex with the 
telomerase catalytic subunit, human telomerase reverse transcriptase (hTERT) [6]. NS 
was originally discovered during research on genes that are highly expressed in neural 
stem cells, embryonic stem (ES) cells, and developing organs during embryogenesis [7]. 
NS functions as a reprogramming factor for induced pluripotent stem (iPS) cells [8], 
indicating that NS is essential for the maintenance of the undifferentiated status of 
ES/iPS cells. In neural stem cells, NS contributes to genomic stability [9], and NS 
deficiency in neural stem cells causes replication-dependent DNA damage that is 
associated with defective self-renewal. In haematopoietic stem cells, NS knockdown 
impairs the long-term reconstitution capacity and induces apoptosis as a result of 
accumulated DNA damage [10]. 
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We previously generated transgenic mice in which green florescent protein 
(GFP) is expressed under the control of a particular region of the NS promoter 
(NS-GFP). In this system, we successfully identified the stem cell population among 
neonatal testicular cells, liver cells, and foetal brain tissues [11,12,13] as well as 
tumour-initiating cells, conceptually termed ‘cancer stem cells,’ in brain tumours and 
germ cell tumours [13,14]. Consistent with our studies, NS-enriched mammary tumour 
cells are highly tumourigenic [15]. Although the mechanisms are still unclear, there are 
particular programs that control NS expression and functions that are also commonly 
involved in maintaining stem cell properties in normal and malignant tissues. Recently, 
a study with newly diagnosed AML patients reported that high expression of NS is 
closely correlated with the percentage of immature blast cells and with haematopoietic 
stem/progenitor cell surface markers and that high NS transcript levels are found in 
AML patients with poor prognosis [16]; this suggests that NS expression may be an 
indicator of immature properties of AML cells. In this study, we prospectively evaluated 
the leukaemia-initiating capacity of subpopulations of AML cells with varying NS 
expression by using NS-GFP transgenic mice. We found that a leukaemia stem cell gene 
signature containing genes differentially expressed in cells with high and low NS 
promoter activity could also be used to stratify human AML patients into distinct 




2. Materials and methods 
2.1. Generation of an AML model  
NS-GFP transgenic mice were generated as described previously [11]. All procedures 
were performed in accordance with the animal care guidelines of Kanazawa University, 







 cells isolated from bone marrow (BM) of NS-GFP 
transgenic mice were infected with a retrovirus carrying Hoxa9 and Meis1a 
(MSCV-Hoxa9-IRES-Meis1a) and transplanted into lethally irradiated syngeneic mice 
along with 5 × 10
5
 normal BM mononuclear cells (rescue cells). 
 
2.2. Leukaemia initiating capacity in vitro and in vivo. 
The leukaemia-initiating capacity of fractionated NS-GFP cells was evaluated with a 
colony formation assay (MethoCult GF M3434, Stem Cell Technologies Inc., Vancouver, 
Canada) and by transplantation into lethally irradiated recipient mice, as previously 
described [18]. 
 
2.3. Cell cycle analysis 
The recipient mice were sacrificed 2 hours after intraperitoneal injection of 
5-bromo-2'-deoxyuridine (BrdU, 100 mg/kg, Sigma-Aldrich., Missouri, USA). The 
fractionated cells were stained with FITC-conjugated anti-BrdU antibody (BD 
Biosciences., New Jersey, USA) and propidium iodide (PI, 20 μg/ml, Sigma-Aldrich). 
 
2.4. Quantitative RT-PCR analysis 
RNA samples were purified from fractionated leukaemia cells (1.5 × 10
4
) using an 
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RNeasy kit (QIAGEN, Tokyo, Japan) and reverse-transcribed using an Advantage 
RT-for-PCR kit (Clontech, Takara Bio Inc., Shiga, Japan). PCR for NS was performed 
using a Dice PCR Thermal Cycler (Takara Bio Inc.) as previously reported [11]. 
 
2.5. Preprocessing of microarray data  
Gene expression profiling of mouse AML cells was performed as described in the 

















 cells, followed by 
cDNA synthesis. cDNA microarray analysis was performed with a GeneChip Mouse 
430 2.0 (Affymetrix Inc., High Wycombe, UK). The complete microarray data set is 
available at the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/, accession 
number GSE 58032). Unsupervised hierarchical clustering was performed on the 
normalized and log-transformed data of 17,419 probes. Similarity was measured by 
Euclidean distance metric, and the average linkage was used to define the linking 
distance between clusters. To select probes whose expression changed progressively 
among the 4 subpopulations, we extracted 3,494 probes that showed gradual increases 
or decreases in expression as AML differentiation increased. Among the 3,494 probes, 









 were extracted. The 500 probes corresponded to 382 mouse gene 
symbols, forming the ‘leukaemia stem cell signature’ shown in Supplementary Table 1. 
Pathway analysis using the 382 mouse gene symbols was performed by using DAVID 
v6.7 (http://david.abcc.ncifcrf.gov/) with Gene Ontology (GO) and Kyoto Encyclopedia 
of Genes and Genomes (KEGG). The 382 mouse gene symbols corresponded to 338 





2.6. Analysis of human AML patient data  
We used data from 179 AML patient samples published by The Cancer Genome Atlas 
Research Network [19] (http://cancergenome.nih.gov/). For patient clustering, we used 
318 human genes from AML patients that are included in the database and were among 
the 338 human genes in the leukaemia stem cell signature. Clustering of AML patients 
was performed by using the R ‘cluster’ package, PAM (Partitioning Around Medoids; 
http://stat.ethz.ch/R-manual/R-patched/library/cluster/html/pam.html).  
 
2.7. Statistical analyses  
For analysis of mouse AML samples, statistical differences among multiple groups were 
evaluated by a one-way ANOVA and Tukey as a post-hoc test. Statistical differences in 
Kaplan-Meier survival curves were determined using the log-rank test. For analysis of 
human AML data, age of patients, initial white blood cell (WBC) number of peripheral 
blood, and percent of blasts among mononuclear BM cells were compared among the 
clusters with Student’s t-test or a one-way ANOVA/Tukey. Patients’ sex, 
French-American-British (FAB) classification, and molecular risk classification were 
compared with Fisher’s exact test and Bonferroni as a post-hoc test. Overall survival 
was plotted using the Kaplan–Meier estimator and compared with the log-rank test. The 
statistical analyses were performed using R software, and a two-sided significance level 






3.1. Fractionation of living AML cells based on NS expression level 
We first investigated whether our NS-GFP reporter system could be used to monitor NS 







mononuclear cells from NS-GFP transgenic mice with a retrovirus expressing both the 
Hoxa9 and Meis1a genes. This procedure generates a well-characterized AML once the 
transduced cells are transplanted into lethally irradiated syngeneic hosts [20]. As 
expected, all recipients of NS-GFP transgenic cells transduced with Hoxa9 and Meis1a 
developed leukaemia. Morphological analysis showed that the recipient BM was filled 
with leukaemia cells, including many blast-like cells and some more mature 
myeloid-like cells such as neutrophils and monocytes (data not shown), which is 
categorized as AML with maturation under the WHO classification (FAB Classification 
M2) [20]. We fractionated the approximately 95% of BM cells that were positive for 
NS-GFP into 3 subpopulations depending on GFP fluorescence intensity: NS-GFP
+++
 
(approximately top 5%), NS-GFP
++ 
(next 45%), and NS-GFP
+ 
(next lower 45%); the 
remaining 5% were NS-GFP
–
 (Fig. 1A). GFP fluorescence intensity in all 4 fractions 
closely paralleled the endogenous NS mRNA expression as measured by RT-PCR (Fig. 
1B).  
 
3.2. Correlation of maturation stages of leukaemia cells with NS-GFP level 
To characterize the fractionated AML cells, we analysed several surface markers for 
haematopoietic differentiation (Fig. 1C). As expected, all 4 fractions expressed the 
myeloid lineage marker Mac-1 but not markers for the T, B, or erythroid lineages. Sca-1, 
which is expressed in haematopoietic stem cells but not myeloid progenitor cells, was 
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not expressed in any of the fractionated cells. Most NS-GFP
+++
 leukaemia cells 
expressed c-Kit, consistent with the positive correlation between NS and c-KIT [16]. 









 cells (Fig. 2A), and 
NS-GFP
–


















, reflecting the combined patterns of NS-GFP and c-Kit expression.  
The morphology of leukaemia cells differed remarkably among the 




 cells appeared to be very immature 




 cells appeared to be mature 
myeloid cells with lobular nuclei. The NS-GFP
middle










 cells were larger than cells in the other subpopulations as evaluated 
by flow cytometry (Fig. 2C). We next examined the gene expression profiles of each of 
the 4 leukaemic cell fractions to see if there was a relationship between GFP 



























 (Fig. 2D). These progressive 























3.3. Characterization of undifferentiated leukaemia cells 
We evaluated the cell cycle status of the fractionated NS-GFP leukaemia cells in vivo by 
measuring BrdU incorporation and DNA content (Fig. 3A). The proportion of 




 cells more than the 
other subpopulations (Fig. 3B), indicating that these immature blast-like cells were 
actively cycling. To characterise the gene signature of undifferentiated leukaemia cells, 
we selected 3,494 probes whose expression gradually increased or decreased along with 
the progressive changes among the 4 subpopulations. Among these 3,494 probes, we 










(Supplementary Table 1). Consistent with the data shown in Fig. 1B, the NS gene was 
included in the gene set. Pathway analysis with the 382 genes showed that cell cycle 
regulators and nucleotide metabolism–related genes were highly enriched 
(Supplementary Table 2). These data are consistent with the dramatic differences in 
cell cycle status between the cell fractions (Fig. 3B). 
 
3.4. Enrichment of LICs in cells expressing high levels of NS-GFP
 
in vitro and in 
vivo 
To investigate properties of the fractionated cells, we performed in vitro colony-forming 









). We found that NS-GFP
+++
 cells exhibited the 





leukaemia cells readily formed colonies, whereas NS-GFP
–
 did not (Fig. 3C), 
indicating that NS expression is correlated with colony-forming ability.  
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Next, we evaluated leukaemia-initiating capacity in vivo with a transplantation 
assay. When we transplanted 100 cells of each of the 4 fractionated leukaemia cell 
populations into separate groups of mice, recipient mice in all groups developed 
leukaemia (data not shown), indicating that the frequency of LICs was very high. 
Therefore, to distinguish between the cell populations, we transplanted 10 cells of each. 
In this condition, we found that only the NS-GFP
+++
 cells generated a secondary 
leukaemia (Fig. 3D). Thus, LICs are enriched in cells with highest level of NS-GFP. 
  
3.5. Association of a murine leukaemia stem cell gene signature with prognosis of 
human AML patients  
Finally, we investigated whether NS is associated with the properties of human AML 
cells. To do so, we first evaluated NS gene expression in human AML patients by using 
the public database developed by the Cancer Genome Atlas (TCGA) Research Network 
[19]. Unexpectedly, we did not find a correlation between human NS expression and 
FAB classification, molecular risk, or prognosis (Supplementary Fig. 1). We therefore 
evaluated the relationship between the leukaemia stem cell gene signature shown above 
and characteristics of AML patients. We selected 318 human genes corresponding to the 
500 mouse probes described above (Supplementary Table 1). Using this human gene 
set, we performed a clustering algorithm related to the k-medoids algorithm 
(Partitioning Around Medoids; PAM) for 179 AML patient samples. Because the 
clustering analysis showed that the average silhouette width was higher for k = 2 or 3 
than for k = 4 or 5, we first stratified AML into two clusters (Cluster 1, n = 34; Cluster 2, 
n = 145) (Fig. 4A). Patients in the two clusters showed significant differences in age, 
number of WBCs, FAB classification, and molecular risks (Supplementary Table 3A). 
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Cluster 1 consisted of younger patients who had lower WBC numbers than patients in 
Cluster 2. All patients with M3 FAB classification were included in Cluster 1, whereas 
all patients whose leukaemia was classified as M0, M6, or M7, which are relatively 
poor prognostic types, were included in Cluster 2 (Fig. 4B). Molecular risk 
classification showed that patients in Cluster 1 exhibited more good prognostic factors 
and fewer intermediate and poor prognostic factors than those in Cluster 2 (Fig. 4C and 
Supplementary Table 3A). Consistent with these findings, the overall survival rate was 
significantly higher for Cluster 1 patients than for Cluster 2 patients (Fig. 4D). When we 
stratified AML patients into three clusters, we found that one cluster mainly consisted of 
patients whose leukaemia was classified as M3 and that there were significant 
differences in prognosis between the clusters (Supplementary Fig. 2 and 
Supplementary Table 3B). Thus, the gene signature of leukaemia stem cells in a mouse 







We successfully identified LICs by monitoring NS expression in a mouse AML model. 
In this system, endogenous NS correlated well with the undifferentiated status of 
leukaemia cells in vivo. In normal haematopoiesis, NS is more highly expressed in 
myeloid progenitors and haematopoietic stem cells than in differentiated haematopoietic 
cells [10]. Because a recent study indicated that AML stem cells are 
immunophenotypically similar to progenitors, including lymphoid-primed multipotent 
progenitors and granulocyte-macrophage progenitors [21], the higher expression of NS 
in myeloid progenitor cells may be conserved in leukaemia stem cells. Our data in the 
AML mouse model suggest that NS plays a critical role in maintaining undifferentiated 
status in AML cells, as has been shown in ES/iPS cells [8].  
There are critical differences in the characteristics of AML between mouse and 
human. We found that NS gene expression itself was not correlated with the prognostic 
characteristics of AML in patients in the TCGA database, which was inconsistent with a 
previously reported result [16]. Although mouse NS was included in the leukaemia stem 
cell gene signature, NS expression levels were not significantly different among AML 
patient clusters in our study (data not shown), presumably due to heterogeneity among 
patients in the regulation of human NS expression. In addition, LICs from patient 
samples and the experimental mice also exhibited critical differences. For example, 




 leukaemia cells 
were actively cycling in our mouse model. Therefore, the gene signature identified in 
this experiment may not be directly associated with the endogenous pattern of NS 
expression. Even though NS itself may not function as a potent driver of malignant 
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status in AML patients, our data suggest that a network of genes associated with NS 
promoter activity affects the malignant status of human and mouse AML cells.  
In clinical investigations, high NS expression is associated with poor prognosis 
in breast cancer [23], oesophageal cancer [24], and gastric and liver cancer [25]. 
Therefore, the core network of the leukaemia stem cell signature may be conserved in 
stem cells in solid tumours. In this study, we identified a gene set associated with AML 
that included cell cycle and nucleotide metabolism–related genes. These genes may 
coordinate stem cell properties with response to DNA damage and telomere stability to 
control self-renewal activity in normal and malignant cells, including solid tumours. 
Further analysis of NS-related genes may contribute to the understanding of the factors 
that regulate a variety of cancers. 
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Fig. 1. Characterization of fractionated AML cells by expression levels of NS-GFP.  
(A) GFP intensity of leukaemia cells derived from NS-GFP transgenic mice. BM cells 
of recipient mice with AML were analysed by flow cytometry and divided into 4 
subfractions according to GFP fluorescence intensity. (B) NS mRNA expression levels. 
Data are presented as the mean ± SD of the ratios of NS to β-actin mRNA copy numbers 
in fractionated cells (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001 (C) Expression of 
surface markers, including CD4, CD8, Mac-1, Gr-1, B220, Ter119, Sca-1 and c-Kit on 
fractionated cells.  
 
Fig. 2. Enrichment of immature blastic leukaemia cells in the NS-high cell 
population. (A) Representative data of NS-GFP and c-Kit expression on BM cells in 


















(B) Morphology of fractionated leukaemia cells. The fractionated AML cells were 
stained with May-Grünwald-Giemsa staining. (C) Representative data from 
forward-scattered (FSC) and side-scattered (SSC) light showing cell size of fractionated 
AML cells. (D) The gene expression profiling of fractionated AML cells. Unsupervised 
hierarchical clustering was performed on the normalized and log-transformed data of 
17,419 probes, similarity was measured by Euclidean distance metric, and the average 
linkage was used to define the linking distance between clusters. Red and green reflect 
high and low expression levels, respectively, as indicated in the scale bar.  
 
Fig. 3. Correlation of NS expression with leukaemia-initiating capacity. (A and B) 
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Cell cycle analysis with BrdU incorporation and DNA content. The leukaemic mice 
were sacrificed 2 hours after BrdU injection, followed by staining of fractionated AML 

















 with an anti-BrdU antibody and 7-AAD. (A) Representative 
data are shown. (B) The data are presented as the mean ± SD of the percentage of 
BrdU
+
 cells among all cells in the fraction (n = 3). ***p< 0.001 (C) Colony-forming 
capacity of fractionated leukaemia cells. The fractionated AML cells shown in Fig. 1A 
were cultured in methylcellulose media. The data shown are the mean ± SD of the 
number of colonies (n = 3). **p< 0.01; ***p< 0.001 (D) Survival of recipient mice with 
fractionated AML cells. Ten leukaemia cells from each fraction shown in Fig. 1A were 
transplanted along with 5 × 10
5
 bone marrow competitor cells (rescue cells) into 
separate lethally irradiated mice. Significant differences between NS-GFP
+++
 and other 
fractionated AML cells were observed. 
 
Fig. 4. Correlation of prognosis of AML patients with the leukaemia stem cell 
signature. (A) Clustering of 179 AML patients by a clustering algorithm (PAM) using 
the leukaemia stem cell gene signature (318 human genes). Clustering data (k = 2) with 
silhouette width are shown. Average silhouette width is 0.63. (B and C) Numbers of 
patients with FAB classification (B) or molecular risk classification (C) are shown. 
(N.C.) not classified. (N.D.) no data. (D) Overall survival of the clustered AML patients. 
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Cluster 1: 0.32 (n=34) 




Preprocessing of microarray data  
Leukaemia cells were sorted into 4 fractions: (a) c-Kit–NS-GFPlow, (b) 
c-Kit–NS-GFPmiddle, (c) c-Kit+NS-GFPmiddle, and (d) c-Kit+NS-GFPhigh. Total RNA from 
2 × 104 cells in each fraction was isolated by using TRIzol (Invitrogen). Microarray 
experiments were carried out using the RNA samples (One RNA sample per fraction). 
Two-cycle cDNA synthesis, in vitro transcription, and labelling were performed 
according to the methods in the GeneChip Expression Analysis Technical Manual 
(Affymetrix Inc., High Wycombe, UK), and the cDNA microarray analysis was 
performed with a GeneChip Mouse 430 2.0 (Affymetrix Inc., High Wycombe, UK). The 
complete microarray data set is available at the Gene Expression Omnibus 
(www.ncbi.nlm.nih.gov/geo/, accession number GSE 58032). Background correction 
and probe summarization were performed by using Microarray Suite version 5.0 (MAS 
5.0), then 17,419 of 45,101 probes were extracted as "present" in all 4 samples. The data 
were normalized with R software. In global normalization, the trimmed mean target 
intensity of each array was arbitrarily set to 500. The expression data were log2 
transformed. 
Unsupervised hierarchical clustering was performed on the normalized and 
log-transformed data of 17,419 probes to obtain the result shown in Fig. 2D. Similarity 
was measured by Euclidean distance metric and the average linkage was used to define 
the linking distance between clusters. To select genes associated with leukaemia stem 
cells, we first extracted 5,474 of 17,419 probes showing 
|log2(c-Kit
+NS-GFPhigh/c-Kit–NS-GFPlow)| ≥ 1, then further selected 3,494 probes that 
exhibited a gradual increase or decrease in expression that paralleled the progressive 
  
changes among the 4 subpopulations by matching the following criteria (1+2+3 or 
4+5+6): (1) c-Kit+NS-GFPhigh ≥ c-Kit+NS-GFPmiddle, (2) c-Kit+NS-GFPmiddle ≥ 
c-Kit–NS-GFPmiddle, (3) c-Kit–NS-GFPmiddle ≥ c-Kit–NS-GFPlow, (4) c-Kit+NS-GFPhigh ≤ 
c-Kit+NS-GFPmiddle, (5) c-Kit+NS-GFPmiddle 
≤ 
≤ c-Kit–NS-GFPmiddle, (6) 
c-Kit–NS-GFPmiddle  c-Kit–NS-GFPlow. Among 3,494 probes, the 500 probes that 
exhibited the largest ratios between c-Kit–NS-GFPlow and c-Kit+NS-GFPhigh were 
extracted. The 500 probes were converted to 382 mouse gene symbols by matching 
GRCm38.p2 of Ensembl database with the R ‘Bioconductor’ package, biomaRt 
(http://www.bioconductor.org/packages/release/bioc/html/biomaRt.html) and are shown 
















Supplementary Fig. 1. Evaluation of human NS gene expression in human AML patients in the 
TCGA Research Network database. (A) Overall survival of patients with high and low NS expression. 
We used RNAseq gene-level RPKM (Reads per kilobase of exon per million mapped reads) data to 
evaluate the NS (GNL3) expression level in AML samples. Patients were divided into two groups based 
on NS levels: NS-High (≥median) and NS-Low (<median). (B) NS expression level among AML samples 
classified by FAB. Horizontal bars indicate the median, and boxes represent the interquartile range (IQR). 
Upper whiskers represent the lower of either the maximum or (75th percentile + IQR × 1.5). Lower 
whiskers represent the higher of either the minimum or (25th percentile – IQR × 1.5). Circles represent 
outliers. M0, n = 16; M1, n = 44; M2, n = 40; M3, n = 16; M4, n = 35; M5, n = 21; M6, n = 2; M7, n = 3l; 
not classified (N.C.), n = 2. There are no significant differences among the groups. 
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Supplementary Fig. 2. Correlation of prognosis of AML patients  with the leukaemia stem cell 
signature. (A) Clustering of 179 AML patients by a clustering algorithm (PAM) using the leukaemia stem 
cell gene signature (318 human genes). Clustering data (k = 3) with average silhouette width are shown. 
Average silhouette width is 0.54. (B and C) Numbers of patients with FAB classification (B) or molecular 
risk classification (C) are shown. (N.C.) not classified. (N.D.) no data. (D) Overall survival of the clustered 















































Cluster 2 Cluster 1 Cluster 3 
Cluster 2 Cluster 1 Cluster 3 
Silhouette Width 
Cluster 3: 0.56 (n=12) 
Cluster 2: 0.54 (n=143) 
Cluster 1: 0.53 (n=24) 
M.mu H.sa M.mu H.sa M.mu H.sa
Abca1 ABCA1 Cdc7 CDC7 Foxred2 FOXRED2
Abca13 ABCA13 Cdca2 CDCA2 Frmd4b FRMD4B
Abca9 ABCA9 Cdca8 CDCA8 Fyb FYB
Acss2 ACSS2 Ceacam1 CEACAM1 Gatm GATM
Acvr1 ACVR1 Ceacam2 CEACAM1 Gbp3 GBP4
Add3 ADD3 Cenpe CENPE Gfi1 GFI1
Adrbk2 ADRBK2 Cenph CENPH Gnl3 GNL3
Agpat4 AGPAT4 Cenpi CENPI Gns GNS
Ahnak AHNAK Cenpn CENPN Golm1 GOLM1
Ahr AHR Cenpp CENPP Gpnmb GPNMB
Akna AKNA Cenpq CENPQ Gpr137b GPR137B
Ampd3 AMPD3 Cep55 CEP55 Gpr146 GPR146
Antxr2 ANTXR2 Chchd10 CHCHD10 Gpr18 GPR18
Anxa6 ANXA6 Chek1 CHEK1 Gsn GSN
Apitd1 APITD1 Cks1b CKS1B Hip1 HIP1
Apobr APOBR Clec10a CLEC10A Hist1h2bq HIST1H2BH
Apoc2 APOC2 Cmss1 CMSS1 Hist1h2br HIST1H2BH
Arsb ARSB Crispld2 CRISPLD2 Hist1h4i HIST4H4
Asns ASNS Csf1r CSF1R Hrsp12 HRSP12
Atp13a2 ATP13A2 Ctsb CTSB Idi1 IDI1
Atp1a3 ATP1A3 Ctse CTSE Ifi203 IFI16
Atp2b1 ATP2B1 Cxcl2 CXCL3 Ifitm3 IFITM3
Atp7a ATP7A Cxcr3 CXCR3 Igfbp4 IGFBP4
Aurka AURKA Cybb CYBB Ikbkb IKBKB
Aurkb AURKB Cyp27a1 CYP27A1 Il17ra IL17RA
Bach1 BACH1 Cyp4f18 CYP4F2 Il4ra IL4R
Bank1 BANK1 Cyth4 CYTH4 Inpp5f INPP5F
Bcas2 BCAS2 Cytip CYTIP Irf5 IRF5
Bcl3 BCL3 Ddi2 DDI2 Itfg3 ITFG3
Bcl6 BCL6 Ddit4 DDIT4 Itgb2 ITGB2
Birc5 BIRC5 Depdc1a DEPDC1 Itgb5 ITGB5
Bmf BMF Dhfr DHFR Itgb7 ITGB7
Brca1 BRCA1 Dnajb14 DNAJB14 Junb JUNB
Bub1 BUB1 Dopey2 DOPEY2 2810417H13Rik KIAA0101
4632428N05Rik C10orf54 Dpp4 DPP4 5031439G07Rik KIAA0930
2310047M10Rik C17orf59 Dtymk DTYMK C330027C09Rik KIAA1524
BC055324 C1orf112 Dusp22 DUSP22 Kif18a KIF18A
BC028528 C1orf54 Dusp3 DUSP3 Kif2c KIF2C
3110043O21Rik C9orf72 Dut DUT Kif4 KIF4A
6330416G13Rik C9orf91 Ect2 ECT2 Klf3 KLF3
Camk1d CAMK1D Egln3 EGLN3 Kmo KMO
Capg CAPG Elane ELANE L1cam L1CAM
Capn2 CAPN2 Elk3 ELK3 Lgals3 LGALS3
Card6 CARD6 Emilin2 EMILIN2 Gm14548 LILRB3
Casp6 CASP6 Epsti1 EPSTI1 Gm15931 LILRB3
Cblb CBLB Errfi1 ERRFI1 Lilra6 LILRB3
Cbx5 CBX5 Evi2a EVI2A Pira2 LILRB3
Ccdc34 CCDC34 Exo1 EXO1 Pirb LILRB3
Ccnd3 CCND3 Fabp5 FABP5 Gp49a LILRB4
Ccne2 CCNE2 Fam129a FAM129A Lilrb4 LILRB4
Ccr2 CCR2 Fam214b FAM214B Lpin1 LPIN1
Cd14 CD14 Fam69a FAM69A Lpp LPP
Cd244 CD244 Fbxl5 FBXL5 Lrp1 LRP1
Cd2ap CD2AP Fcgrt FCGRT Lrr1 LRR1
AF251705 CD300C Fgr FGR Lsp1 LSP1
Cd300lf CD300LF Fignl1 FIGNL1 Map1lc3a MAP1LC3A
Cd97 CD97 Filip1l FILIP1L Map4k4 MAP4K4
Cdc14b CDC14B Fnip2 FNIP2 Mapk1 MAPK1
(1/3)
Supplementary Table 1. Leukaemia stem cell signature.
M.mu H.sa M.mu H.sa M.mu H.sa
Matn2 MATN2 Ppat PPAT Ssh2 SSH2
Mef2a MEF2A Prex1 PREX1 St6gal1 ST6GAL1
Melk MELK Prim1 PRIM1 Stk10 STK10
Mfsd6 MFSD6 Prkag2 PRKAG2 Stx3 STX3
Mgam MGAM Psmc3ip PSMC3IP Suclg2 SUCLG2
Mis18bp1 MIS18BP1 Ptgfrn PTGFRN Syce2 SYCE2
Mitf MITF Ptplad2 PTPLAD2 Tbc1d1 TBC1D1
Mmp8 MMP8 Ptpn1 PTPN1 Tcf25 TCF25
Mns1 MNS1 Ptpro PTPRO Tep1 TEP1
Mpo MPO Rab19 RAB19 Tfpi TFPI
Ms4a3 MS4A3 Rab43 RAB43 Tgfbr2 TGFBR2
Mthfd1 MTHFD1 5430435G22Rik RAB7B Timm8a1 TIMM8A
Mvp MVP Rad51 RAD51 Tk1 TK1
Myadm MYADM Rad51ap1 RAD51AP1 Tle1 TLE1
Mybl2 MYBL2 Rad54l RAD54L Tlr2 TLR2
Ncapg NCAPG Rap1gap2 RAP1GAP2 Tmcc1 TMCC1
Ncapg2 NCAPG2 Rbl1 RBL1 Tmem107 TMEM107
Ncaph NCAPH Rfc4 RFC4 Tmem71 TMEM71
Nckap1l NCKAP1L Rgcc RGCC Tmem86a TMEM86A
Ncl NCL Rhoq RHOQ Tnfrsf1b TNFRSF1B
Ncoa3 NCOA3 Rnase4 RNASE4 Top2a TOP2A
Ndc1 NDC1 Rnf128 RNF128 Trp53inp1 TP53INP1
Ndrg1 NDRG1 Rrm1 RRM1 Tpd52 TPD52
Nek2 NEK2 Rrm2 RRM2 Tpx2 TPX2
Nfam1 NFAM1 S100a9 S100A9 Traip TRAIP
Nfil3 NFIL3 Samd9l SAMD9L Trim37 TRIM37
Nfkbiz NFKBIZ Samhd1 SAMHD1 Trip13 TRIP13
Nop58 NOP58 Sema4a SEMA4A Trip6 TRIP6
Npc2 NPC2 Sema4d SEMA4D Trpm2 TRPM2
Nrip1 NRIP1 Serf1 SERF1A Trpv2 TRPV2
Nrp1 NRP1 Serpinb1a SERPINB1 Tspan17 TSPAN17
Nsl1 NSL1 Sfxn5 SFXN5 Ttk TTK
Nt5c3b NT5C3B Sgms1 SGMS1 Ttll3 TTLL3
Nudcd2 NUDCD2 Sgol2 SGOL2 Tube1 TUBE1
Nudt5 NUDT5 Sh2b3 SH2B3 Tulp4 TULP4
Nup43 NUP43 Sh3bp5 SH3BP5 Ube2h UBE2H
Odc1 ODC1 Shcbp1 SHCBP1 Unc119 UNC119
Olfm1 OLFM1 Shisa5 SHISA5 Unc119b UNC119B
Osbpl3 OSBPL3 Ska1 SKA1 Usp1 USP1
P2rx7 P2RX7 Sla SLA Utrn UTRN
Pag1 PAG1 Slc11a1 SLC11A1 Wdr12 WDR12
Pbk PBK Slc12a4 SLC12A4 Wee1 WEE1
Peli1 PELI1 Slc12a9 SLC12A9 Xdh XDH
Pfas PFAS Slc16a1 SLC16A1 Ypel3 YPEL3
Pfkfb4 PFKFB4 Slc28a2 SLC28A2 Zbtb4 ZBTB4
Phgdh PHGDH Slc2a6 SLC2A6 Zfhx3 ZFHX3
Pid1 PID1 Slc43a2 SLC43A2 Zwilch ZWILCH
Pik3r5 PIK3R5 Slc44a1 SLC44A1 Zyx ZYX
Pik3r6 PIK3R6 Slc7a7 SLC7A7 Ccl6 N/A
Pip4k2a PIP4K2A Slfn8 SLFN13 Cd33 N/A
Pitpnm1 PITPNM1 Slfn9 SLFN13 Clec4a3 N/A
Pld4 PLD4 Smc2 SMC2 Fabp5l2 N/A
Plec PLEC Smim5 SMIM5 Fnbp1l N/A
Plek PLEK Snrpd1 SNRPD1 Gm10693 N/A
Plekhg2 PLEKHG2 Spc24 SPC24 Gm14085 N/A
Plekhm3 PLEKHM3 Spdl1 SPDL1 Gm14328 N/A
Plk4 PLK4 Sqstm1 SQSTM1 Gm14928 N/A






































The 382 mouse (M.mu) genes that showed the largest ratios between c-Kit-NS-GFPlow and c-Kit+NS-GFPhigh
 
and the 338 corresponding human (H.sa) gene symbols are shown.
GO:0034654~nucleobase, nucleoside, nucleotide and
nucleic acid biosynthetic process
13 1.59E-04 0.238365 0.017989 0.268817
GO:0034404~nucleobase, nucleoside and nucleotide
biosynthetic process
13 1.59E-04 0.238365 0.017989 0.268817
< GO term : Molecular Function >
Term Count p-value Bonferroni Benjamini FDR
GO:0017076~purine nucleotide binding 69 3.96E-10 1.67E-07 1.67E-07 5.57E-07
GO:0001882~nucleoside binding 61 6.75E-10 2.85E-07 1.43E-07 9.49E-07
GO:0032555~purine ribonucleotide binding 66 1.36E-09 5.73E-07 1.91E-07 1.91E-06
GO:0032553~ribonucleotide binding 66 1.36E-09 5.73E-07 1.91E-07 1.91E-06
GO:0030554~adenyl nucleotide binding 59 2.95E-09 1.24E-06 3.11E-07 4.14E-06
GO:0001883~purine nucleoside binding 59 4.04E-09 1.71E-06 3.41E-07 5.68E-06
GO:0032559~adenyl ribonucleotide binding 56 9.61E-09 4.06E-06 6.76E-07 1.35E-05
GO:0005524~ATP binding 55 1.72E-08 7.25E-06 1.04E-06 2.42E-05
GO:0000166~nucleotide binding 72 1.80E-08 7.59E-06 9.48E-07 2.53E-05
GO:0004674~protein serine/threonine kinase activity 21 3.66E-05 0.015344 0.001717 0.051494
GO:0019900~kinase binding 9 9.96E-05 0.041166 0.004195 0.139929
GO:0004672~protein kinase activity 24 1.64E-04 0.066901 0.006275 0.230383
GO:0019901~protein kinase binding 8 2.03E-04 0.082273 0.007129 0.285575
< GO term : Cellular Component >
Term Count p-value Bonferroni Benjamini FDR
GO:0000775~chromosome, centromeric region 20 8.19E-14 1.99E-11 1.99E-11 1.06E-10
GO:0005694~chromosome 32 1.14E-12 2.77E-10 1.39E-10 1.48E-09
GO:0044427~chromosomal part 28 1.65E-11 4.00E-09 1.33E-09 2.13E-08
GO:0000793~condensed chromosome 17 6.75E-11 1.64E-08 4.10E-09 8.73E-08
GO:0000779~condensed chromosome, centromeric region 11 9.60E-08 2.33E-05 4.66E-06 0.000124
GO:0000776~kinetochore 11 1.33E-07 3.22E-05 5.37E-06 0.000172
GO:0000777~condensed chromosome kinetochore 10 3.62E-07 8.79E-05 1.26E-05 0.000468
GO:0043228~non-membrane-bounded organelle 61 6.29E-06 0.001527 0.000191 0.008132
GO:0043232~intracellular non-membrane-bounded 61 6.29E-06 0.001527 0.000191 0.008132
GO:0045121~membrane raft 8 0.000814 0.179536 0.021747 1.047653
GO:0000794~condensed nuclear chromosome 6 0.000875 0.191542 0.021038 1.125259
 
 
< GO term : Biological Process >
 
 Term Count p-value Bonferroni Benjamini FDR 
 
GO:0000279~M phase 28 4.69E-12 8.00E-09 8.00E-09 7.91E-09  
GO:0022402~cell cycle process 32 1.65E-11 2.82E-08 1.41E-08 2.79E-08  
GO:0007049~cell cycle 40 2.30E-11 3.93E-08 1.31E-08 3.89E-08  
GO:0022403~cell cycle phase 29 2.67E-11 4.56E-08 1.14E-08 4.51E-08  
GO:0051301~cell division 26 1.37E-10 2.34E-07 4.67E-08 2.31E-07  
GO:0000280~nuclear division 20 3.57E-09 6.09E-06 1.02E-06 6.02E-06  
GO:0007067~mitosis 20 3.57E-09 6.09E-06 1.02E-06 6.02E-06  
GO:0000087~M phase of mitotic cell cycle 20 5.06E-09 8.63E-06 1.23E-06 8.53E-06  
GO:0048285~organelle fission 20 6.53E-09 1.11E-05 1.39E-06 1.10E-05  
GO:0000278~mitotic cell cycle 22 7.93E-09 1.35E-05 1.50E-06 1.34E-05  
GO:0007059~chromosome segregation 10 3.09E-06 0.005258 5.27E-04 0.005212  
GO:0006955~immune response 26 3.52E-06 0.005987 5.46E-04 0.005937  
GO:0001775~cell activation 16 7.32E-05 0.117444 0.010357 0.123429  
GO:0045321~leukocyte activation 15 7.66E-05 0.122500 0.010002 0.129103  




Supplementary Table 2. Pathway analysis of the 382 mouse genes performed by DAVID v6.7
with GO and KEGG. 
The significance of enrichment was evaluated by a modified Fisher’s exact test. The pathways that 
showed significant enrichment (corrected p < 0.05) are shown. The Bonferroni correction was 
used to correct for multiple comparisons and to control the family-wise error rate. The false 
discovery rate (FDR) was controlled with the Benjamini-Hochberg procedure. Counts indicate the
number of genes corresponding to individual terms.
Cluster 1 Cluster 2(n = 34) (n = 145) p-value
Age (years old) median (range) 50 (23-76) 60 (18-88) 0.0038
Sex Male / Female 17 / 17 77 / 68 0.8491
WBC (×10
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Cluster 1 Cluster 2 Cluster 3 post h  oc
(n = 24) (n = 143) (n = 12) p- v  alue p (corr) <   0.05
50 (21-76) 60 (18-88) 46 (29-68) 0.005 Cluster 2 - Cluster 1







0.034 Cluster 3 - Cluster 2
4.24E-14
Cluster 2 - Cluster 1
Cluster 3 - Cluster 1
Cluster 3 - Cluster 2
M0 0 16 0
M1 6 38 0
M2 10 29 1
M3 5 0 11
M4 3 32 0
M5 0 21 0
M6 0 2 0
M7 0 3 0










2.51E-13 Cluster 2 - Cluster 1
Cluster 3 - Cluster 2
Good 13 10 11
Intermediat 7 86 0
Poor 1 2 0
N.D. 3 45 1
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